Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of hematology and oncology Ročník 12; číslo 1; s. 47 - 11
Hlavní autori: Yang, Sen, Zhang, Zhe, Wang, Qiming
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 02.05.2019
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
Cancer therapies
Cancer treatment
Carboplatin
Care and treatment
Chemotherapy
Clinical trials
Cytotoxicity
Drug dosages
Hematology
Humans
Immunotherapy
Immunotherapy - methods
Ipilimumab
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Methods
Monoclonal antibodies
Neutropenia
Oncology
Orphan drugs
Pembrolizumab
Review
RNA polymerase
Small cell lung cancer
Small cell lung carcinoma
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - pathology
Targeted cancer therapy
Targeted therapy
China
Small cell lung cancer
Chemotherapy
Targeted therapy
Immunotherapy
ISSN:1756-8722, 1756-8722
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
AbstractList Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC. Keywords: Small cell lung cancer, Chemotherapy, Immunotherapy, Targeted therapy
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
Abstract Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI drugs. Innovative clinical trial designs are needed to efficiently explore the increasing number of options with new drugs and new combinations thereof for SCLC.
ArticleNumber 47
Audience Academic
Author Wang, Qiming
Zhang, Zhe
Yang, Sen
Author_xml – sequence: 1
  givenname: Sen
  surname: Yang
  fullname: Yang, Sen
  organization: Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
– sequence: 2
  givenname: Zhe
  surname: Zhang
  fullname: Zhang, Zhe
  organization: Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
– sequence: 3
  givenname: Qiming
  orcidid: 0000-0003-3217-1077
  surname: Wang
  fullname: Wang, Qiming
  email: qimingwang1006@126.com
  organization: Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31046803$$D View this record in MEDLINE/PubMed
BookMark eNp9kt1r1TAYxotM3If-Ad7IAUG86cx30hthjOkGA2_0OqTpm54c2uSYtAP_e1PP3M4ZUwptSH7P8zYPz2l1FGKAqnqL0TnGSnzKmCLGa4SbGkkqavqiOsGSi1pJQo721sfVac4bhARuCHpVHVOMmFCInlT11Qip96FfTWtIZushr1xMqzyaYVhZKK9hLqfWBAvpdfXSmSHDm_vvWfXjy9X3y-v69tvXm8uL29oKyqa6ZZxZTFpQSFlmmFGYKiupM1Q6TiUFYRjvMOMAuOuMEoa3nDgDzrmmAXpW3ex8u2g2epv8aNIvHY3XfzZi6rVJk7cDaMYR5pQw20HLhGRNR3lrZVuuJzBvXfH6vPPazu0InYUwJTMcmB6eBL_WfbzTgjWKN7QYfLw3SPHnDHnSo89LMiZAnLMmhDSEioargr5_gm7inEKJaqEkUpRQ_Ej1plzABxfLXLuY6guuBGeIqIU6f4YqTwejt6UIzpf9A8GHPcEazDCtcxzmyceQD8F3-4k8RPG3FQXAO8CmmHMC94BgpJfm6V3zdGmeXpqnF418orF-Msvs8tt--K-S7JS5TAk9pMfQ_i36DTPD6Fw
CitedBy_id crossref_primary_10_3389_fimmu_2024_1493740
crossref_primary_10_1038_s41420_022_01296_8
crossref_primary_10_1097_MD_0000000000035526
crossref_primary_10_1159_000542769
crossref_primary_10_1002_cam4_2668
crossref_primary_10_1002_cam4_5813
crossref_primary_10_3389_fonc_2021_628693
crossref_primary_10_1155_2020_8811487
crossref_primary_10_1016_j_semcancer_2022_05_004
crossref_primary_10_3389_fonc_2023_1151769
crossref_primary_10_1016_j_lungcan_2020_07_026
crossref_primary_10_1016_j_nano_2020_102261
crossref_primary_10_1016_j_jrras_2023_100575
crossref_primary_10_1007_s12032_023_02019_4
crossref_primary_10_52547_ibj_3732
crossref_primary_10_1038_s41388_024_03027_y
crossref_primary_10_1007_s12094_024_03390_y
crossref_primary_10_2147_OTT_S235349
crossref_primary_10_1016_j_cbi_2023_110588
crossref_primary_10_3389_fimmu_2022_1059557
crossref_primary_10_3389_fimmu_2023_1237978
crossref_primary_10_3390_biomedicines11020389
crossref_primary_10_1186_s12957_022_02595_1
crossref_primary_10_3389_fgene_2022_919857
crossref_primary_10_1007_s11864_025_01342_4
crossref_primary_10_1002_cam4_4736
crossref_primary_10_2217_bmm_2023_0723
crossref_primary_10_1136_jitc_2021_002554
crossref_primary_10_3389_bjbs_2022_10498
crossref_primary_10_1155_2022_6280538
crossref_primary_10_1007_s40265_020_01398_6
crossref_primary_10_1016_j_biopha_2022_113458
crossref_primary_10_3389_fcell_2021_778020
crossref_primary_10_1097_MD_0000000000025709
crossref_primary_10_3389_fimmu_2019_02801
crossref_primary_10_3389_fonc_2022_781903
crossref_primary_10_1039_D1NR02791C
crossref_primary_10_3390_app14209344
crossref_primary_10_1186_s12913_023_09727_7
crossref_primary_10_3390_jfb14090466
crossref_primary_10_1177_15593258211055016
crossref_primary_10_3390_nu12030671
crossref_primary_10_3389_fimmu_2025_1613368
crossref_primary_10_1007_s00280_021_04265_7
crossref_primary_10_1002_cam4_4507
crossref_primary_10_1136_bmjopen_2023_072106
crossref_primary_10_1186_s13073_020_00735_4
crossref_primary_10_1016_j_jtocrr_2022_100400
crossref_primary_10_3390_ma13235397
crossref_primary_10_1002_mco2_70112
crossref_primary_10_3389_fonc_2022_894835
crossref_primary_10_1634_theoncologist_2020_0193
crossref_primary_10_1016_j_canlet_2023_216426
crossref_primary_10_3390_cancers13143500
crossref_primary_10_1038_s41419_024_06563_3
crossref_primary_10_1136_bmjopen_2021_056895
crossref_primary_10_3892_or_2025_8981
crossref_primary_10_1016_j_intimp_2019_106088
crossref_primary_10_3389_fimmu_2022_1059331
crossref_primary_10_1111_1759_7714_14842
crossref_primary_10_3389_fonc_2020_00741
crossref_primary_10_3389_fphar_2022_932098
crossref_primary_10_1080_09553002_2021_1976860
crossref_primary_10_3390_life12010114
crossref_primary_10_1016_j_omton_2024_200788
crossref_primary_10_17650_2782_3202_2024_4_3_45_49
crossref_primary_10_1186_s12906_021_03204_6
crossref_primary_10_1097_JCMA_0000000000000576
crossref_primary_10_1007_s11684_021_0916_8
crossref_primary_10_1158_1535_7163_MCT_23_0524
crossref_primary_10_1016_j_lungcan_2025_108630
crossref_primary_10_3390_biomedicines10092121
crossref_primary_10_1016_j_cpt_2022_09_001
crossref_primary_10_1186_s12931_025_03327_1
crossref_primary_10_1177_10732748211028257
crossref_primary_10_3390_biomedicines9111665
crossref_primary_10_1186_s12951_023_01958_4
crossref_primary_10_1016_j_ctarc_2020_100167
crossref_primary_10_3389_fonc_2022_729088
crossref_primary_10_3389_fonc_2023_1162181
crossref_primary_10_3390_molecules25194435
crossref_primary_10_3390_ijms26083666
crossref_primary_10_1186_s13019_025_03513_8
crossref_primary_10_1016_j_heliyon_2023_e21328
crossref_primary_10_1177_10225536251380326
crossref_primary_10_3390_diagnostics11020174
crossref_primary_10_3390_biomedicines12010123
crossref_primary_10_1136_bmjopen_2021_052556
crossref_primary_10_3390_ph17050598
crossref_primary_10_1039_C9RA06267J
crossref_primary_10_3390_biomedicines10020428
crossref_primary_10_2147_CMAR_S319650
crossref_primary_10_1016_j_esmoop_2025_104514
crossref_primary_10_1016_j_lungcan_2023_02_003
crossref_primary_10_61958_NMKH3071
crossref_primary_10_3389_fgene_2023_1160915
crossref_primary_10_1080_07391102_2023_2257803
crossref_primary_10_3389_fendo_2023_1132915
crossref_primary_10_1007_s13304_023_01708_z
crossref_primary_10_2169_internalmedicine_4808_24
crossref_primary_10_3389_fphar_2023_1170344
crossref_primary_10_2174_1570180820666230914104206
crossref_primary_10_1002_cac2_12351
crossref_primary_10_1186_s12890_023_02681_4
crossref_primary_10_1007_s13258_022_01306_0
crossref_primary_10_1097_MD_0000000000033432
crossref_primary_10_1111_cbdd_14570
crossref_primary_10_3389_fonc_2023_1103512
crossref_primary_10_1016_j_biopha_2019_109401
crossref_primary_10_1016_j_intimp_2025_114116
crossref_primary_10_2147_LCTT_S492825
crossref_primary_10_1080_14479338_2023_2204322
crossref_primary_10_1002_cam4_4132
crossref_primary_10_1111_cas_16450
crossref_primary_10_1177_10781552231178461
crossref_primary_10_3390_cancers13112629
crossref_primary_10_1002_cbin_11674
crossref_primary_10_1007_s00203_022_03194_0
crossref_primary_10_1093_jjco_hyaa077
crossref_primary_10_1111_1759_7714_14712
crossref_primary_10_1016_j_arbres_2019_10_023
crossref_primary_10_1007_s11684_024_1107_1
crossref_primary_10_1002_adbi_202400119
crossref_primary_10_1155_2022_4484211
crossref_primary_10_3389_fimmu_2024_1333850
crossref_primary_10_1016_j_ijrobp_2021_12_009
crossref_primary_10_1016_j_bmc_2025_118299
crossref_primary_10_1016_j_bbrc_2025_151707
crossref_primary_10_3389_fnano_2021_635194
crossref_primary_10_1155_2022_2010341
crossref_primary_10_2217_fon_2021_1027
crossref_primary_10_1155_2022_5244820
crossref_primary_10_2147_OTT_S337331
crossref_primary_10_1016_j_toxicon_2024_107641
crossref_primary_10_3389_fonc_2024_1504139
crossref_primary_10_7759_cureus_35561
crossref_primary_10_1016_j_biopha_2020_111213
crossref_primary_10_1259_bjr_20210228
crossref_primary_10_1016_j_compbiomed_2022_105638
crossref_primary_10_3390_ijms22115820
crossref_primary_10_3389_fphar_2021_784335
crossref_primary_10_1080_23311908_2025_2496022
crossref_primary_10_1186_s12645_023_00174_x
crossref_primary_10_1002_cam4_5360
crossref_primary_10_1007_s13659_024_00455_x
crossref_primary_10_1080_14737140_2021_1996230
crossref_primary_10_1186_s13045_019_0819_1
crossref_primary_10_3390_cells10081879
crossref_primary_10_3389_fonc_2022_904865
crossref_primary_10_1158_1541_7786_MCR_22_0881
crossref_primary_10_1186_s12957_021_02449_2
crossref_primary_10_1097_MPA_0000000000001794
crossref_primary_10_3389_fimmu_2021_782775
crossref_primary_10_1021_acsami_4c16840
crossref_primary_10_3389_fonc_2020_602185
crossref_primary_10_1016_j_lungcan_2025_108484
crossref_primary_10_1016_j_sbsr_2025_100826
crossref_primary_10_1016_j_arbr_2020_04_003
crossref_primary_10_1097_CAD_0000000000001552
crossref_primary_10_4155_bio_2023_0143
crossref_primary_10_1016_j_mrfmmm_2022_111791
crossref_primary_10_3389_fonc_2024_1394286
crossref_primary_10_1002_jcla_24772
crossref_primary_10_1016_j_ijnurstu_2022_104430
crossref_primary_10_3390_cells11233826
crossref_primary_10_3389_fendo_2021_672499
crossref_primary_10_1002_cmdc_202500260
crossref_primary_10_1038_s41598_024_65314_8
crossref_primary_10_1002_ange_202013406
crossref_primary_10_1007_s11096_024_01792_0
crossref_primary_10_1186_s12962_021_00329_w
crossref_primary_10_1016_j_arcmed_2023_102897
crossref_primary_10_2147_IJGM_S338250
crossref_primary_10_1155_2021_2105176
crossref_primary_10_1186_s12951_023_01768_8
crossref_primary_10_1080_1120009X_2021_1906036
crossref_primary_10_1016_j_vacune_2024_05_013
crossref_primary_10_1016_j_critrevonc_2025_104616
crossref_primary_10_3389_fimmu_2023_1223020
crossref_primary_10_1080_07357907_2023_2220820
crossref_primary_10_1016_j_jtho_2021_06_022
crossref_primary_10_2147_IJN_S362759
crossref_primary_10_1007_s00432_019_03064_1
crossref_primary_10_3389_fcvm_2022_922811
crossref_primary_10_1002_onco_13752
crossref_primary_10_1016_j_critrevonc_2023_104136
crossref_primary_10_3390_cancers13071723
crossref_primary_10_2147_PPA_S299399
crossref_primary_10_1007_s12672_024_01119_5
crossref_primary_10_2147_CMAR_S249678
crossref_primary_10_3389_fphar_2024_1398667
crossref_primary_10_1038_s41420_023_01629_1
crossref_primary_10_1080_14728222_2020_1723548
crossref_primary_10_1186_s12885_023_10797_3
crossref_primary_10_3390_cancers13092101
crossref_primary_10_1016_j_yexcr_2022_113075
crossref_primary_10_1186_s12964_024_01980_5
crossref_primary_10_1038_s41392_021_00641_0
crossref_primary_10_1136_bmjopen_2023_077090
crossref_primary_10_1111_odi_14404
crossref_primary_10_1016_j_biopha_2023_116014
crossref_primary_10_1016_j_critrevonc_2023_104247
crossref_primary_10_1080_08830185_2024_2333275
crossref_primary_10_1097_MD_0000000000029251
crossref_primary_10_31083_j_fbl2812357
crossref_primary_10_1186_s13045_021_01173_4
crossref_primary_10_2174_0109298673278897231229121524
crossref_primary_10_1007_s11051_024_06008_0
crossref_primary_10_1136_bmjopen_2024_087302
crossref_primary_10_1002_anie_202013406
crossref_primary_10_1016_j_jconrel_2024_11_026
crossref_primary_10_18553_jmcp_2022_21379
crossref_primary_10_3390_cancers13061187
crossref_primary_10_1002_cam4_5738
crossref_primary_10_1002_slct_202402903
crossref_primary_10_1177_17588359251356919
crossref_primary_10_1111_crj_13819
crossref_primary_10_1111_cas_15653
crossref_primary_10_1186_s12575_023_00217_y
crossref_primary_10_3390_cancers15153980
crossref_primary_10_3389_fimmu_2023_1227797
crossref_primary_10_1097_CAD_0000000000001119
crossref_primary_10_3390_ijms22031349
crossref_primary_10_1177_11795549211067184
crossref_primary_10_1111_1759_7714_14543
crossref_primary_10_1002_ijc_34629
crossref_primary_10_1002_cai2_43
crossref_primary_10_1088_2057_1976_ad9f69
crossref_primary_10_1007_s11033_023_08612_0
crossref_primary_10_1016_j_jrras_2022_100482
crossref_primary_10_1097_MD_0000000000027138
crossref_primary_10_7759_cureus_29989
crossref_primary_10_1097_MD_0000000000037759
crossref_primary_10_3389_fphar_2020_00843
crossref_primary_10_1016_j_ctarc_2023_100684
crossref_primary_10_1016_j_molimm_2021_10_002
crossref_primary_10_1016_j_lfs_2020_118985
crossref_primary_10_1186_s12894_019_0560_7
crossref_primary_10_1002_cai2_155
crossref_primary_10_1111_1759_7714_14679
crossref_primary_10_1097_CAD_0000000000001588
crossref_primary_10_2147_CMAR_S275624
crossref_primary_10_1016_j_semcancer_2022_11_012
crossref_primary_10_1016_j_heliyon_2023_e22913
crossref_primary_10_3389_fimmu_2022_1025125
crossref_primary_10_1016_j_prp_2022_154083
crossref_primary_10_1186_s12880_025_01691_4
crossref_primary_10_1002_cam4_5750
crossref_primary_10_3390_jcm13113120
crossref_primary_10_1016_j_mcp_2023_101918
crossref_primary_10_2147_IJGM_S426590
crossref_primary_10_2147_CMAR_S364125
crossref_primary_10_4103_jcrt_jcrt_855_21
crossref_primary_10_1007_s12253_020_00832_0
crossref_primary_10_1016_j_canlet_2023_216352
crossref_primary_10_1186_s12957_021_02410_3
crossref_primary_10_3389_fphar_2022_959938
crossref_primary_10_3389_fonc_2020_01079
crossref_primary_10_1007_s12325_021_01909_1
crossref_primary_10_1016_j_bbcan_2022_188798
crossref_primary_10_1016_j_soncn_2024_151657
crossref_primary_10_2196_59152
crossref_primary_10_1016_j_mseb_2022_116047
crossref_primary_10_1136_bmjopen_2019_034685
crossref_primary_10_1080_14786419_2023_2269592
crossref_primary_10_1097_CM9_0000000000002818
crossref_primary_10_1155_2021_7773163
crossref_primary_10_1007_s12032_023_02005_w
crossref_primary_10_1186_s12906_024_04363_y
crossref_primary_10_3389_fonc_2022_852885
crossref_primary_10_1186_s13046_020_01682_z
crossref_primary_10_1097_CAD_0000000000001488
crossref_primary_10_1007_s10753_022_01701_5
crossref_primary_10_1016_j_biopha_2024_116909
crossref_primary_10_1155_2022_2528164
crossref_primary_10_2147_IJGM_S353045
crossref_primary_10_1111_cts_12928
crossref_primary_10_1136_bmjopen_2020_039660
crossref_primary_10_1002_pat_5749
Cites_doi 10.1016/S1470-2045(16)30104-8
10.1200/JCO.2017.72.5069
10.1016/j.jtho.2018.08.308
10.1186/s40164-019-0129-x
10.1016/j.jtho.2016.05.028
10.1634/theoncologist.2009-0298
10.1634/theoncologist.2015-0498
10.1016/S1470-2045(16)30098-5
10.1200/JCO.2006.06.5821
10.1126/scitranslmed.aac9459
10.1056/NEJMoa1507643
10.1053/j.seminoncol.2010.09.015
10.1073/pnas.0915174107
10.1158/1538-7445.AM2019-CT073
10.1634/theoncologist.2017-0204
10.6004/jnccn.2013.0011
10.1200/JCO.2018.36.15_suppl.8507
10.1186/s13045-017-0479-y
10.1073/pnas.0712237105
10.1038/sj.onc.1207316
10.6004/jnccn.2011.0094
10.1186/s13045-017-0456-5
10.1200/JCO.2011.40.4905
10.1016/j.jtho.2016.09.010
10.1186/s13045-018-0664-7
10.1038/nature14011
10.1002/cam4.317
10.1200/JCO.2018.36.15_suppl.8517
10.1200/JCO.2002.06.110
10.1093/annonc/mds213
10.1126/science.271.5256.1734
10.1007/s40262-018-0701-2
10.1056/NEJMoa1809064
10.1056/NEJMoa1504627
10.1016/1074-7613(94)90071-X
10.1158/1078-0432.CCR-09-1339
10.1200/JCO.2017.35.15_suppl.8504
10.1158/1078-0432.CCR-11-2059
10.1200/JCO.2018.77.7672
10.1186/s13045-017-0506-z
10.1200/JCO.2018.36.15_suppl.8506
10.1158/1078-0432.CCR-06-2318
10.1186/s13045-017-0541-9
10.1200/JCO.2016.67.6601
10.1038/nature08629
10.1158/1078-0432.CCR-17-2805
10.1007/978-3-319-24223-1_1
10.1111/cas.13536
10.1007/978-3-319-40389-2_14
10.1016/j.jtho.2016.09.008
10.1200/jco.2015.33.15_suppl.4516
10.1056/NEJMoa1709937
10.1007/s13577-016-0149-3
10.1021/tx049793j
10.1056/NEJMoa1504030
10.1001/jamaoncol.2018.3039
10.1186/s13045-018-0684-3
10.1124/jpet.113.203828
10.1200/JCO.2008.20.1061
10.1183/09031936.00105009
10.1016/j.pharmthera.2017.06.002
10.2217/imt.10.21
10.1158/2159-8290.CD-12-0112
10.1093/hmg/ddq529
10.1200/JCO.2018.36.15_suppl.8570
ContentType Journal Article
Copyright The Author(s). 2019
COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s). 2019
– notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13045-019-0736-3
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
ProQuest Health & Medical Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE



Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 11
ExternalDocumentID oai_doaj_org_article_45015324cdeb46749d35bc7b680615bf
PMC6498593
A586540281
31046803
10_1186_s13045_019_0736_3
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Henan Provincial Research Program of Application Foundation and Advanced Technology
  grantid: 112300410033
– fundername: Henan Provincial Special Funds for Health and Technological Innovative Talents
  grantid: 2011020155
– fundername: Henan Province and Ministry of Health of Medical Science and Technology Program
  grantid: 201601026
– fundername: Wu Jieping Medical Foundation for Clinical Research
  grantid: 320.6799.15018
– fundername: Medical Science and Technology Foundation of Henan Province
  grantid: 201601026
– fundername: the 51282 project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents
  grantid: [2016]32
– fundername: National Natural Science Foundation of China
  grantid: 81272600
– fundername: Program for Science and Technology Innovation Talents in Universities of Henan Province
  grantid: 18HASTIT044
– fundername: Henan Provincial Training Abroad Foundation for Leaders of Medical Science
  grantid: 201082
– fundername: ;
  grantid: 2011020155
– fundername: ;
  grantid: 18HASTIT044
– fundername: ;
  grantid: 201082
– fundername: ;
  grantid: 201601026
– fundername: ;
  grantid: 112300410033
– fundername: ;
  grantid: [2016]32
– fundername: ;
  grantid: 320.6799.15018
– fundername: ;
  grantid: 81272600
GroupedDBID ---
0R~
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
AAYXX
AFFHD
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c634t-b454c12be808c4a4a8138c73fa37f5373e6a45d145ee1dda86a5b52faefff99e3
IEDL.DBID RSV
ISICitedReferencesCount 326
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000466909400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1756-8722
IngestDate Tue Oct 14 19:03:23 EDT 2025
Tue Nov 04 01:59:21 EST 2025
Fri Sep 05 06:47:17 EDT 2025
Sun Oct 19 00:04:43 EDT 2025
Tue Nov 11 10:05:15 EST 2025
Tue Nov 04 17:32:29 EST 2025
Thu May 22 21:09:18 EDT 2025
Thu Apr 03 06:59:22 EDT 2025
Tue Nov 18 21:26:58 EST 2025
Sat Nov 29 06:33:48 EST 2025
Sat Sep 06 07:21:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Small cell lung cancer
Chemotherapy
Targeted therapy
Immunotherapy
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c634t-b454c12be808c4a4a8138c73fa37f5373e6a45d145ee1dda86a5b52faefff99e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-3217-1077
OpenAccessLink https://link.springer.com/10.1186/s13045-019-0736-3
PMID 31046803
PQID 2227083231
PQPubID 54946
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_45015324cdeb46749d35bc7b680615bf
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6498593
proquest_miscellaneous_2229236958
proquest_journals_2227083231
gale_infotracmisc_A586540281
gale_infotracacademiconefile_A586540281
gale_healthsolutions_A586540281
pubmed_primary_31046803
crossref_primary_10_1186_s13045_019_0736_3
crossref_citationtrail_10_1186_s13045_019_0736_3
springer_journals_10_1186_s13045_019_0736_3
PublicationCentury 2000
PublicationDate 2019-05-02
PublicationDateYYYYMMDD 2019-05-02
PublicationDate_xml – month: 05
  year: 2019
  text: 2019-05-02
  day: 02
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of hematology and oncology
PublicationTitleAbbrev J Hematol Oncol
PublicationTitleAlternate J Hematol Oncol
PublicationYear 2019
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References M Reck (736_CR27) 2013; 24
SM Gadgeel (736_CR36) 2017; 35
E Arriola (736_CR26) 2016; 11
BJ Schneider (736_CR7) 2011; 9
G Chapman (736_CR54) 2011; 20
A Rossi (736_CR11) 2012; 30
TK Owonikoko (736_CR53) 2018; 3
TK Owonikoko (736_CR47) 2014; 3
H Borghaei (736_CR37) 2015; 373
LR Saunders (736_CR55) 2015; 7
A Somasundaram (736_CR63) 2017; 1
MC Pietanza (736_CR51) 2012; 18
TL Walunas (736_CR18) 1994; 1
JMT Perez (736_CR17) 2018; 15
J Larkin (736_CR41) 2015; 373
RJ Cardnell (736_CR48) 2013; 347
V Verma (736_CR65) 2019; 8
736_CR57
A Hoos (736_CR22) 2010; 37
LV Sequist (736_CR30) 2016; suppl_6
SL Gerson (736_CR49) 2002; 9
LA Byers (736_CR46) 2012; 2
K Goto (736_CR15) 2016; 17
EJ Small (736_CR23) 2007; 13
SJ Antonia (736_CR67) 2017; 377
M Reck (736_CR28) 2016; 31
G Shen (736_CR60) 2018; 1
L Horn (736_CR31) 2018; 379
D Liu (736_CR14) 2017; 1
C Xie (736_CR58) 2018; 109
MF Krummel (736_CR19) 2011; 7
M Esteller (736_CR50) 2004; 23
Y Cheng (736_CR61) 2018; 13
TE Stinchcombe (736_CR9) 2017; 22
A Lallo (736_CR68) 2018; 20
HJ Hammers (736_CR40) 2015; 33
T Ito (736_CR12) 2017; 30
J Sul (736_CR32) 2016; 5
R Singh (736_CR45) 2005; 18
RS Herbst (736_CR29) 2014; 515
C Fernandez-Teruel (736_CR16) 2018; 58
GP Kalemkerian (736_CR2) 2013; 1
FS Hodi (736_CR25) 2008; 105
DR Leach (736_CR20) 1996; 271
MC Pietanza (736_CR52) 2018; 36
DB Page (736_CR21) 2010; 2
SJ Antonia (736_CR42) 2016; 11S
ED Pleasance (736_CR5) 2010; 7278
Z Li (736_CR64) 2018; 1
HC Chung (736_CR34) 2018; 15
B Han (736_CR59) 2018; 4
PA Ott (736_CR33) 2017; 35
SY Liu (736_CR62) 2017; 1
LA Torre (736_CR1) 2016; 893
IK Demedts (736_CR4) 2010; 35
736_CR35
B Liu (736_CR66) 2017; 1
SN Waqar (736_CR8) 2017; 180
SJ Antonia (736_CR43) 2016; 17
MER O’Brien (736_CR13) 2006; 24
J Brahmer (736_CR38) 2015; 373
DC Cho (736_CR44) 2018; 36
EB Bernhardt (736_CR6) 2016; 170
TE Stinchcombe (736_CR3) 2010; 15
SM Ansell (736_CR24) 2009; 15
MA Curran (736_CR39) 2010; 107
TM Bauer (736_CR56) 2016; 11S
PN Lara (736_CR10) 2009; 27
References_xml – volume: 17
  start-page: 1147
  issue: 8
  year: 2016
  ident: 736_CR15
  publication-title: Lancet Oncology
  doi: 10.1016/S1470-2045(16)30104-8
– volume: 35
  start-page: 3823
  issue: 34
  year: 2017
  ident: 736_CR33
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.72.5069
– volume: 13
  start-page: S351
  year: 2018
  ident: 736_CR61
  publication-title: J Thorac Oncol.
  doi: 10.1016/j.jtho.2018.08.308
– volume: 8
  start-page: 5
  year: 2019
  ident: 736_CR65
  publication-title: Exp Hematol Oncol.
  doi: 10.1186/s40164-019-0129-x
– volume: 11
  start-page: 1511
  issue: 9
  year: 2016
  ident: 736_CR26
  publication-title: J Thorac Oncol.
  doi: 10.1016/j.jtho.2016.05.028
– volume: 15
  start-page: 187
  issue: 2
  year: 2010
  ident: 736_CR3
  publication-title: Oncologist.
  doi: 10.1634/theoncologist.2009-0298
– volume: 5
  start-page: 643
  issue: 21
  year: 2016
  ident: 736_CR32
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2015-0498
– volume: 17
  start-page: 883
  issue: 7
  year: 2016
  ident: 736_CR43
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30098-5
– volume: 24
  start-page: 5441
  issue: 34
  year: 2006
  ident: 736_CR13
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.5821
– volume: 7
  start-page: 302ra136
  issue: 302
  year: 2015
  ident: 736_CR55
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.aac9459
– volume: 373
  start-page: 1627
  issue: 17
  year: 2015
  ident: 736_CR37
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1507643
– volume: 37
  start-page: 533
  issue: 5
  year: 2010
  ident: 736_CR22
  publication-title: Semin Oncol.
  doi: 10.1053/j.seminoncol.2010.09.015
– volume: 107
  start-page: 4275
  issue: 9
  year: 2010
  ident: 736_CR39
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.0915174107
– ident: 736_CR35
  doi: 10.1158/1538-7445.AM2019-CT073
– volume: 22
  start-page: 1510
  issue: 12
  year: 2017
  ident: 736_CR9
  publication-title: Oncologist.
  doi: 10.1634/theoncologist.2017-0204
– volume: 1
  start-page: 78
  issue: 11
  year: 2013
  ident: 736_CR2
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2013.0011
– ident: 736_CR57
  doi: 10.1200/JCO.2018.36.15_suppl.8507
– volume: 1
  start-page: 110
  issue: 10
  year: 2017
  ident: 736_CR14
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0479-y
– volume: 105
  start-page: 3005
  issue: 8
  year: 2008
  ident: 736_CR25
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.0712237105
– volume: 23
  start-page: 1
  issue: 1
  year: 2004
  ident: 736_CR50
  publication-title: Oncogene.
  doi: 10.1038/sj.onc.1207316
– volume: 9
  start-page: 1132
  issue: 10
  year: 2011
  ident: 736_CR7
  publication-title: J Natl Compr Canc Netw.
  doi: 10.6004/jnccn.2011.0094
– volume: 1
  start-page: 87
  issue: 10
  year: 2017
  ident: 736_CR63
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0456-5
– volume: 30
  start-page: 1692
  issue: 14
  year: 2012
  ident: 736_CR11
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2011.40.4905
– volume: 11S
  start-page: S252
  issue: 11
  year: 2016
  ident: 736_CR56
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.09.010
– volume: 1
  start-page: 120
  issue: 11
  year: 2018
  ident: 736_CR60
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0664-7
– volume: 515
  start-page: 563
  issue: 7528
  year: 2014
  ident: 736_CR29
  publication-title: Nature.
  doi: 10.1038/nature14011
– volume: 3
  start-page: 1579
  issue: 6
  year: 2014
  ident: 736_CR47
  publication-title: Cancer Med.
  doi: 10.1002/cam4.317
– volume: 36
  start-page: 8517
  issue: 15_suppl
  year: 2018
  ident: 736_CR44
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2018.36.15_suppl.8517
– volume: 9
  start-page: 2388
  issue: 20
  year: 2002
  ident: 736_CR49
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.06.110
– volume: 7
  start-page: 3459
  issue: 187
  year: 2011
  ident: 736_CR19
  publication-title: J Immunol
– volume: 24
  start-page: 75
  issue: 1
  year: 2013
  ident: 736_CR27
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mds213
– volume: 271
  start-page: 1734
  issue: 5256
  year: 1996
  ident: 736_CR20
  publication-title: Science.
  doi: 10.1126/science.271.5256.1734
– volume: 58
  start-page: 363
  issue: 3
  year: 2018
  ident: 736_CR16
  publication-title: Clin Pharmacokinet
  doi: 10.1007/s40262-018-0701-2
– volume: 379
  start-page: 2220
  issue: 23
  year: 2018
  ident: 736_CR31
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1809064
– volume: 373
  start-page: 123
  issue: 2
  year: 2015
  ident: 736_CR38
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1504627
– volume: 1
  start-page: 405
  issue: 5
  year: 1994
  ident: 736_CR18
  publication-title: Immunity.
  doi: 10.1016/1074-7613(94)90071-X
– volume: 15
  start-page: 6446
  issue: 20
  year: 2009
  ident: 736_CR24
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1339
– volume: 35
  start-page: 8504
  issue: 15_suppl
  year: 2017
  ident: 736_CR36
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2017.35.15_suppl.8504
– volume: 18
  start-page: 1138
  issue: 4
  year: 2012
  ident: 736_CR51
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-2059
– volume: 36
  start-page: 2386
  issue: 23
  year: 2018
  ident: 736_CR52
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2018.77.7672
– volume: 1
  start-page: 136
  issue: 10
  year: 2017
  ident: 736_CR62
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0506-z
– volume: 15
  start-page: 8506
  issue: 36
  year: 2018
  ident: 736_CR34
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.15_suppl.8506
– volume: 13
  start-page: 1810
  issue: 6
  year: 2007
  ident: 736_CR23
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-2318
– volume: 1
  start-page: 174
  issue: 10
  year: 2017
  ident: 736_CR66
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0541-9
– volume: 31
  start-page: 3740
  issue: 34
  year: 2016
  ident: 736_CR28
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.67.6601
– volume: suppl_6
  start-page: 1425PD
  issue: 27
  year: 2016
  ident: 736_CR30
  publication-title: Ann Oncol
– volume: 7278
  start-page: 184
  issue: 463
  year: 2010
  ident: 736_CR5
  publication-title: Nature
  doi: 10.1038/nature08629
– volume: 20
  start-page: 5153
  issue: 24
  year: 2018
  ident: 736_CR68
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2805
– volume: 893
  start-page: 1
  year: 2016
  ident: 736_CR1
  publication-title: Adv Exp Med Biol.
  doi: 10.1007/978-3-319-24223-1_1
– volume: 109
  start-page: 1207
  issue: 4
  year: 2018
  ident: 736_CR58
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13536
– volume: 170
  start-page: 301
  year: 2016
  ident: 736_CR6
  publication-title: Cancer Treat Res.
  doi: 10.1007/978-3-319-40389-2_14
– volume: 11S
  start-page: S250
  issue: 11
  year: 2016
  ident: 736_CR42
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.09.008
– volume: 33
  start-page: 4516
  issue: 15_suppl
  year: 2015
  ident: 736_CR40
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2015.33.15_suppl.4516
– volume: 377
  start-page: 1919
  issue: 20
  year: 2017
  ident: 736_CR67
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1709937
– volume: 30
  start-page: 1
  issue: 1
  year: 2017
  ident: 736_CR12
  publication-title: Hum Cell
  doi: 10.1007/s13577-016-0149-3
– volume: 18
  start-page: 249
  issue: 2
  year: 2005
  ident: 736_CR45
  publication-title: Chem Res Toxicol.
  doi: 10.1021/tx049793j
– volume: 373
  start-page: 23
  issue: 1
  year: 2015
  ident: 736_CR41
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1504030
– volume: 3
  start-page: 222
  issue: 37
  year: 2018
  ident: 736_CR53
  publication-title: J Clin Oncol
– volume: 4
  start-page: 1569
  issue: 11
  year: 2018
  ident: 736_CR59
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2018.3039
– volume: 1
  start-page: 142
  issue: 11
  year: 2018
  ident: 736_CR64
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0684-3
– volume: 347
  start-page: 117
  issue: 1
  year: 2013
  ident: 736_CR48
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.113.203828
– volume: 27
  start-page: 2530
  issue: 15
  year: 2009
  ident: 736_CR10
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.1061
– volume: 35
  start-page: 202
  issue: 1
  year: 2010
  ident: 736_CR4
  publication-title: Eur Respir J
  doi: 10.1183/09031936.00105009
– volume: 180
  start-page: 16
  year: 2017
  ident: 736_CR8
  publication-title: Pharmacol Ther.
  doi: 10.1016/j.pharmthera.2017.06.002
– volume: 2
  start-page: 367
  issue: 3
  year: 2010
  ident: 736_CR21
  publication-title: Immunotherapy.
  doi: 10.2217/imt.10.21
– volume: 2
  start-page: 798
  issue: 9
  year: 2012
  ident: 736_CR46
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0112
– volume: 20
  start-page: 905
  issue: 5
  year: 2011
  ident: 736_CR54
  publication-title: Hum Mol Genet.
  doi: 10.1093/hmg/ddq529
– volume: 15
  start-page: 8570
  issue: 36
  year: 2018
  ident: 736_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.36.15_suppl.8570
SSID ssj0061920
Score 2.6234758
SecondaryResourceType review_article
Snippet Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress...
Abstract Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 47
SubjectTerms Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
Cancer therapies
Cancer treatment
Carboplatin
Care and treatment
Chemotherapy
Clinical trials
Cytotoxicity
Drug dosages
Hematology
Humans
Immunotherapy
Immunotherapy - methods
Ipilimumab
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Methods
Monoclonal antibodies
Neutropenia
Oncology
Orphan drugs
Pembrolizumab
Review
RNA polymerase
Small cell lung cancer
Small cell lung carcinoma
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - pathology
Targeted cancer therapy
Targeted therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9VAEB-kFPEi1s_YViMIghKazX4fq1i8WDwo9LbsJxaeqbz36t_fnWySNhX14jU7C5vfzuzM7OzMALxWSZNIA2k6bnXDfKcaR0PXuCB1ax1XLS3NJuTpqTo7019utPrCN2GlPHAB7ojxrLCy1vchOuyMoQPlzksnFCpjl_D0zVbP5EyVMxi9gimGSZQ42hAMCGa3GRN2qGjoQgsNxfp_P5Jv6KTb7yVvBU0HXXTyAO6PRmR9XBa_B3di_xDufh7D5I-gwasm7D5Ul_Sq7A3X2TitNz_salXjXX29ykJee9zy9WP4dvLx64dPzdgXofGCsm3jGGeedC6qVnlmmVWEKi9pslQmTiWNwjIeCOMxkhCsEpY73iUbU0paR_oEdvqLPj6DOnrepuAZVu1j1GdjkUgpecpfnFYpVNBOOBk_Fg3H3hUrMzgPSpgCrcnQGoTW0ArezlN-looZfyN-j-DPhFjseviQWcCMLGD-xQIVvMStMyVzdBZZc8yVyAZpp0gFbwYKFNq8fG_H3IMMApa_WlAeLCizsPnl8MQeZhT2jcF04mzJZku5glfzMM7EB2x9vLgcaLIpLTRXFTwt3DT_NMU4exaKCuSCzxaoLEf68-9DKXDBNBasq-DdxJHXy_oj6M__B-j7cK8b5AkT_A9gZ7u-jIew639tzzfrF4M0XgFq6DMf
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFiEuvB-BAkFCQgJFTWI7tk-oRa24sKoQSL1ZfkKlJVs2W34_nsRJSRG9cI3HUux5-LPH_gbgtQiy8sRVRc20LKitRWGIqwvjuCy1YaIkQ7EJvlyKkxN5nA7cunStcoyJfaB2a4tn5Hv4ZjPChQhH3p_9LLBqFGZXUwmN67CDTGV0ATsHh8vjz2Msxt3BmMusRLPXVZgYjNtnfLhDmoLMVqOetP_v0PzH2nT53uSl5Gm_Jh3d-d_R3IXbCY3m-4P53INrvr0PNz-lfPsDKPDMCssY5cM7rbitziPKzbsferXK8dA_X8VokVu0nc1D-Hp0-OXDxyIVWChsQ-i2MJRRW9XGi1JYqqkWFRGWk6AJD4xw4htNmaso875yTotGM8PqoH0IQUpPHsGiXbf-CeTesjI4S5H-jxIbUWfFOWchfjFSBJdBOU60sol9HItgrFS_CxGNGnSjom4U6kaRDN5OXc4G6o2rhA9Qe5Mgsmb3H9abbyo5oaIsgp-IIK3zBqusSEeYsdw0AoGdCRm8RN2r4Qnq5Ptqn4kmIttaVBm86SXQ--PvW50eMcRJQB6tmeTuTDJ6rZ03j4ahUtTo1IVVZPBqasaeeBOu9evzXiZi8kYykcHjwRynQRNM2EfvyoDPDHU2K_OW9vR7zyneUInMdxm8G0364rf-OelPrx7EM7hV966GHAC7sNhuzv1zuGF_bU-7zYvkqr8BkTZDDw
  priority: 102
  providerName: ProQuest
Title Emerging therapies for small cell lung cancer
URI https://link.springer.com/article/10.1186/s13045-019-0736-3
https://www.ncbi.nlm.nih.gov/pubmed/31046803
https://www.proquest.com/docview/2227083231
https://www.proquest.com/docview/2229236958
https://pubmed.ncbi.nlm.nih.gov/PMC6498593
https://doaj.org/article/45015324cdeb46749d35bc7b680615bf
Volume 12
WOSCitedRecordID wos000466909400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: RBZ
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: M~E
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1756-8722
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061920
  issn: 1756-8722
  databaseCode: RSV
  dateStart: 20081201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB7RFiFeuI9AWYKEhASKSOIzjy1qBQ9drcqh5cmyHRsqLVm02fL78TgHpBwSvESKPZacycz4s8czA_BU-qpwpC6ykukqo7aUmSF1mZlaVLk2TOakKzYh5nO5XFaLPo67HW67Dy7JaKmjWkv-si3QqRe2vhh0Q3hGdmAvrHYStfH07YfB_OKGYHBf_nbYZAGKefp_tcY_LUcXr0pe8JfGZej4-n99wA241qPO9KATk5twyTW34MpJ71e_DRmeTWG5orSLxwrb5zSg2bT9olerFA_301WwCqlFGdncgffHR-9evc76QgqZ5YRuM0MZtUVpnMylpZpqWRBpBfGaCM-III5ryuqCMueKutaSa2ZY6bXz3leVI3dht1k37j6kzrLc15Zimj9KbECXhRCC-dBiKunrBPKBu8r2Wcax2MVKxd2G5KpjgwpsUMgGRRJ4Pg752qXY-BvxIf6ykRCzY8eG9eaT6pVNURZATkCKtnYGq6lUNWHGCsMlAjjjE3iMP1x1oaajjqsDJnlAsKUsEngWKVDLw_St7oMVAhMwX9aEcn9CGbTTTrsHoVK9dWgVxh8H6BugdQJPxm4ciTfeGrc-jzQBe_OKyQTudTI4fjRBx3zQogTERDonXJn2NGefY-5wTivMcJfAi0FGf0zrj0x_8E_UD-FqGYUcQ__3YXe7OXeP4LL9tj1rNzPYEUsRn3IGe4dH88XpLB6EhLfFm5PFx1lU5--4-z1u
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qUwRc2JdAoUECIYGiJrGdOAeEylJ11M5oDkVqT8YrjDTMlMkUxJ_iN-KXraSI3nrgGr9EjvO9z895G8Az7orEEpNEKZNFRHXKI0VMGimTF7FUjMekbjaRj8f88LCYrMGvNhcGwypbTqyI2iw0_iPfwpxNby54c-TN8bcIu0ahd7VtoVHDYs_-_OGPbOXr4Xv_fZ-n6c6Hg3e7UdNVINIZoatIUUZ1kirLY66ppJInhOucOElyx0hObCYpMwll1ibGSJ5JpljqpHXOFYUl_rmXYJ16sPMBrE-Go8lRy_14Gml9pwnPtsoEHZH-uI6JQiSLSG_3q5oE_L0V_LEXno3TPOOsrfbAnRv_2-rdhOuNtR1u1-pxC9bs_DZcGTXxBHcgwn9y2KYprPPQprYMvRUfll_lbBaiUyOceTYMNerG8i58vJDJ3oPBfDG3DyC0msXOaIrlDSnR3qpO8jxnzl9RBXcmgLj9sEI31dWxycdMVKcsnokaC8JjQSAWBAngZXfLcV1a5Dzht4iWThCrglcXFsvPoiEZQZk37ryFrI1V2EWmMIQpnauMo-GqXACbiDVRp9h23Ca2Gc-85Z7yJIAXlQSym5--lk2Shl8ErBPWk9zoSXpW0v3hFoiiYcVSnKIwgKfdMN6JkX5zuzipZPyZIysYD-B-Df_upQkGJHj2CCDvKUZvVfoj8-mXqmZ6Rgus7BfAq1aFTqf1z0V_eP5LbMLV3YPRvtgfjvcewbW0UnOsd7ABg9XyxD6Gy_r7alounzQ0EcKni9at3_rtojY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zi9RAEC50lWVfvI_o6kYQBCVskr4f12NQ1GHBg31r-tSF2cwymfX325VjNOsB4mu6GpLqqu6vUl1fATyWUVWB-KqomVEFdbUsLPF1Yb1QpbFMlqRvNiHmc3l0pA6HPqfteNt9TEn2NQ3I0tSs90997F1c8v22wgRfCoOxAIfwglyESxR7BmG4_uHzuBVjcDCmMn87bXIYdZz9v-7MPx1N569NnsuddkfS7Op_f8w1uDKg0fygN5_rcCE0N2D7_ZBvvwkF_rPCNkZ5X6eVwuo8ody8PTGLRY4__fNF2i1yh7azugWfZq8-vnhdDA0WCscJXReWMuqq2gZZSkcNNbIi0gkSDRGREUECN5T5irIQKu-N5IZZVkcTYoxKBXIbtpplE-5CHhwro3cU6f8ocQl1VkIIFtMTq2T0GZSjprUb2MexCcZCd1GI5LpXg05q0KgGTTJ4uply2lNv_E34OS7fRhBZs7sHy9UXPTihpiyBn4QgnQ8Wu6woT5h1wnKJwM7GDPZw8XVfgrrxfX3AJE_ItpZVBk86CfT-9PrODEUMSQnIozWR3J1IJq910-HRwPSwa7Qa65ITJE6QO4NHm2GciTfhmrA862QSJueKyQzu9Pa4-WiCCfvkXRmIiaVOtDIdaY6_dpzinCpkvsvg2WivP17rj0q_90_Se7B9-HKm372Zv70PO3Vn78gOsAtb69VZeACX3bf1cbt62Pnwd3-1QyY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emerging+therapies+for+small+cell+lung+cancer&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Yang%2C+Sen&rft.au=Zhang%2C+Zhe&rft.au=Wang%2C+Qiming&rft.date=2019-05-02&rft.pub=BioMed+Central&rft.eissn=1756-8722&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-019-0736-3&rft.externalDocID=10_1186_s13045_019_0736_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon